Related Experiment Video
Updated: Jun 6, 2026
06:48
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
Splenic marginal zone lymphoma in 5 dogs (2001-2008)
D Stefanello1, P Valenti, E Zini
1Department of Veterinary Clinical Sciences, School of Veterinary Medicine, University of Milan, Milan, Italy.
Journal of Veterinary Internal Medicine
|November 25, 2010
Summary
Splenic marginal zone lymphoma (MZL) in dogs is a slow-progressing cancer. Splenectomy, with or without chemotherapy, offers a positive prognosis for canine splenic MZL.
Area of Science:
- Veterinary Oncology
- Canine Lymphoma Research
Background:
- Splenic marginal zone lymphoma (MZL) originates from B-cell follicles in dogs.
- This canine lymphoma can exhibit slow progression.
Purpose of the Study:
- To document clinical characteristics, therapeutic interventions, and outcomes for dogs diagnosed with splenic MZL.
- To evaluate the efficacy of splenectomy and chemotherapy in managing canine splenic MZL.
Main Methods:
- Retrospective review of clinical, laboratory, and follow-up data from five dogs with naturally occurring splenic MZL.
- Diagnosis confirmed via histopathological and immunophenotypic analyses.
Main Results:
- All dogs presented with stage IV disease; two experienced symptomatic splenic rupture.
- Four dogs received splenectomy and doxorubicin chemotherapy, with three surviving long-term (760-1825 days) from unrelated causes and one achieving complete remission (445 days).
- One dog treated with surgery alone experienced tumor recurrence at 180 days.
Conclusions:
- Canine splenic MZL is an indolent lymphoma.
- Splenectomy is a beneficial treatment, potentially enhanced by adjuvant systemic chemotherapy.
